Validation of a Predictive Score for HAST
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03728595|
Recruitment Status : Unknown
Verified March 2019 by The Leeds Teaching Hospitals NHS Trust.
Recruitment status was: Recruiting
First Posted : November 2, 2018
Last Update Posted : April 1, 2019
Patients with chronic lung diseases travelling by plane often suffer with symptoms related to lower oxygen levels they are exposed to while flying.
Therefore, patients with respiratory conditions are routinely assessed to establish if they need supplemental oxygen in flight. A hypoxic altitude simulation test (HAST) is often part of this assessment and consists in having patients breathe a oxygen/nitrogen blend with a lower oxygen concentration compared to normal room air, simulating in-flight conditions. Oxygen levels are measured before and after the test through a blood sample (from the earlobe or an artery in the wrist) and with a finger probe. In-flight oxygen is required if the oxygen level in the blood is lower than 6.6 kPa. HASTs are time consuming, costly, and require a dedicated hospital appointment.
Using historical data, the Investigators developed scores based on capillary blood gas (blood sample from the earlobe), diagnosis and sex to predict the outcome of the HASTs. The Investigators validated the proposed scores in a separate historic cohort of patients and showed it had good concordance with the HASTs results.
In this study, the Investigators want to confirm prospectively if the score, based on blood results (venous and/or earlobe), can predict the outcome of the HASTs and therefore reduce the number of tests performed, travel time for patients, and costs for the NHS.
All patients, aged 18 or older, who are having a HAST for clinical purposes at the cardio-respiratory lab at Leeds Teaching Hospital NHS Trust will be invited to take part in the study. The Investigators will record diagnosis, results of HAST and previous spirometry from the medical notes, perform a spirometry if not done in the previous 12 months and collect a blood sample (one tube, 4 mls). With these data, the Investigators will calculate the score and assess its agreement with the outcome of the HAST.
Each participant's involvement in the study will last for approximately 90-120 minutes, which is the normal duration of a HAST.
The Investigators aim to include up to 280 subjects in the study.
|Condition or disease||Intervention/treatment|
|Chronic Respiratory Disease Hypoxia, Altitude COPD ILD Cystic Fibrosis||Diagnostic Test: Venepuncture Diagnostic Test: Spirometry Diagnostic Test: Hypoxic altitude simulation test (HAST)|
|Study Type :||Observational|
|Estimated Enrollment :||280 participants|
|Official Title:||A Predictive Score to Reduce the Use of Hypoxic-altitude Simulation Test (HAST) in Patients With Chronic Respiratory Disease Planning Air Travel - an External Validation Prospective Study|
|Actual Study Start Date :||October 29, 2018|
|Estimated Primary Completion Date :||July 2021|
|Estimated Study Completion Date :||July 2021|
Patients with lung disease having HAST
Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:
Diagnostic Test: Venepuncture
A blood sample will be taken for serum bicarbonate
Diagnostic Test: Spirometry
All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
Diagnostic Test: Hypoxic altitude simulation test (HAST)
HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
- ROC AUC for Model 1 (3*SaO2 - HCO3 - 4 if ILD - 4 if F -3 if COPD), and the relative sensitivity, specificity, positive and negative predictive value of the threshold identified for negative and positive HAST [ Time Frame: Up to 36 months ]The score based on Model 1 will be computed for all subjects and ROC curve analyses will be used to assess predictive value. Sensitivity, specificity, PPV and NPV for criteria previously identified in a historic cohort will be assessed.
- ROC AUC for the simplified score (3*SpO2 - sHCO3 - 4 if ILD - 4 if F - 3 if COPD) [ Time Frame: Up to 36 months ]The simplified score will be computed for all subjects. ROC analyses will be performed and criteria to identify negative and positive HAST at 95%, 97.5% and 99% will be chosen.
- ROC AUC for Model 2, and Model 3 and for baseline pO2 and relative sensitivity, specificity, positive and negative predictive value of the previously identified thresholds. [ Time Frame: Up to 36 months ]The scores based on Model 2 and 3 will be computed for all subjects and ROC curve analyses will be used to assess predictive value. Sensitivity, specificity, PPV and NPV for criteria previously identified in a historic cohort will be assessed.
- Negative and positive predictive value for the criteria chosen for the simplified score. [ Time Frame: Up to 36 months ]Criteria to maximise specificity for negative and positive HAST, respectively, will be chosen for the simplified score (Outcome 2). NPV and PPV for these criteria will be assessed.
- Identification of a new predictive model for the outcome of the HAST [ Time Frame: Up to 36 months ]Exploratory outcome: in case the previously identified models will not be validated, a new score will be developed using binary logistic regression analysis.
- Identification of a model to predict the flow-rate of oxygen required by patients who have a positive HAST. [ Time Frame: Up to 36 months ]During the HAST flow-rate of oxygen is titrated for patients with a positive outcome. As exploratory outcome we aim to develop a model to predict the final flow-rate required for patients who need oxygen in flight.
Biospecimen Retention: Samples Without DNA
The Investigator will collect a blood sample to be processed for serum bicarbonate.
As processing a sample for serum bicarbonate is very susceptible to pre-analytical sources of error, samples will be analysed immediately after collection and then discarded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03728595
|Contact: Giulia Spoletini||+44 email@example.com|
|St James's University Hospital, LTHT||Recruiting|
|Leeds, West Yorkshire, United Kingdom, LS9 7TF|
|Contact: Giulia Spoletini +44 01132069106 firstname.lastname@example.org|
|Principal Investigator:||Giulia Spoletini||Leeds Teaching Hospital NHS Trust|